×

Getmapping is a leading provider of cutting-edge geospatial data and solutions in the UK, with over 25 years of expertise in capturing and delivering high-resolution aerial imagery, LiDAR, mobile mapping, and web-based streaming services.

Further information can be found on the Company’s website: https://www.getmapping.co.uk/

Close

×

RNS Number : 7780D

Vela Technologies PLC

07 March 2022

 

7 March 2022

Vela Technologies plc

("Vela" or "the Company")

Update re. St George Street Capital Limited COVID-19 trial

 

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made by St George Street Capital ("SGSC") which provides an update on the positive outcome of the ARCADIA COVID-19 therapy trial.

Under an agreement entered into in August 2019, SGSC acquired the right to develop and commercialise two assets from a major global pharmaceutical company, one of which includes the licence to a drug that could be beneficial to diabetic patients suffering with COVID-19 (the "Asset"). Details of Vela's economic interest in the potential commercialisation of the Asset, the Asset and the ARCADIA trial were included in the announcement published by Vela on 20 October 2020.

 

James Normand, Director of Vela, commented:

"This update from SGSC indicates that the promise shown by earlier test results (which we have reported on previously) is being maintained.  We are pleased that the latest analysis of the results of the study of the application of the AZD1656 treatment is sufficiently encouraging to result in active engagement with potential commercial partners; and thus to vindicate our decision to invest.  We remain confident that the AZD1656 treatment has the potential to show a healthy return for SGSC and therefore for Vela."

 

Full details of the joint press release issued today by SGSC and Excalibur Medicines Ltd ("EML"), a biotechnology investment company, is extracted below. The Asset is referred to in the press release below as AZD1656:

 

Further analysis of data from the ARCADIA clinical study confirms that the addition of AZD1656 treatment to standard care resulted in fewer deaths and earlier hospital discharge in COVID-19 patients than did placebo treatment.

The ARCADIA Phase II multi-centre study was undertaken in over 150 diabetic patients hospitalised due to moderate to severe COVID-19 infection. Patients received either AZD1656 or placebo daily for up to 21 days in addition to standard care and antidiabetic medications. To be clear, all patients in the trial received standard of care treatment (over 70% in both groups received dexamethasone) with those in the drug group receiving AZD1656 in addition. No deaths occurred in those receiving AZD1656 in the first week of treatment, whereas six deaths occurred in the placebo group. All-cause mortality rates within 28 days of admission favoured the AZD1656 patients, with only four deaths occurring, versus nine deaths in the placebo group.

Thirty patients in the AZD1656 group (38%) were discharged from hospital within seven days of admission, but only 18 patients (25%) receiving placebo treatment. AZD1656 treatment was shown to be safe and well-tolerated.

In addition to the clinical benefit observed in this high-risk patient group, the immunological data gathered from the trial strongly supports SGSC's rationale for the ARCADIA study by confirming that AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of COVID-19 infection, while enhancing the virus-specific immune response.

Thus far, only a small number of repurposed or repositioned drugs have demonstrated benefits in treating COVID-19 infection in early clinical study1. SGSC believes that AZD1656 has the potential to become a valuable addition to the very small number of available COVID-19 drug treatments, offering a safer and more effective alternative to immunomodulatory treatments such as dexamethasone and other steroids, infused anti-cytokines (such as tocilizumab) and Janus kinase inhibitors2.

AZD1656 has an important advantage over small molecule and antibody antiviral agents in that due to its immodulatory effect, efficacy is unlikely to be compromised in treating disease caused by new coronavirus variants. The highly infectious Omicron variant appears to be associated with milder disease symptoms and lower hospitalisation rates, but we may not be so fortunate with future variants. "Variant agnostic", readily stockpiled, transported and easily administered treatments such as AZD1656 are essential for future pandemic preparedness.

SGSC is actively engaged in commercial discussions with appropriate global and regional pharmaceutical companies, with the objective of outright sale, partnership in future development or securing funding for the additional clinical studies necessary to get this to market. Ideally AZD1656 would be evaluated in broader non-diabetic patient populations, both hospitalised patients and those at higher risk of hospitalisation due to underlying health conditions. Despite the unknowns around the evolution of the pandemic, SGSC believes that AZD1656 has the potential to generate significant long-term revenue.

The COVID-19 pandemic has been truly global, and SGSC believes that AZD1656 could be particularly valuable in countries where limited hospital resources, low vaccine uptake and a high prevalence of vulnerable individuals have conspired to push up hospitalisation and death rates.

About AZD1656

AZD1656 was originally developed by AstraZeneca as a diabetes treatment and has an extensive record of safety in clinical studies involving more than one thousand subjects.  Preclinical data suggested a likely immune mode of action, leading SGSC to secure a licence to the agent as a therapy for inflammatory conditions.

In addition to the ARCADIA study supported by EML, the Mubadala Sovereign Wealth Fund, Chlodwig Enterprises and UKRI / Innovate UK, SGSC has actively built on the scope of AZD1656 through patent filing (COVID-19 combination treatment) and intends to exploit the beneficial immunomodulatory effect in immune dysfunction applications.

 

[1] COVID-19 early treatment: real-time analysis of 1,489 studies. https://c19early.com . Accessed 3rd Match 2022

[2] NIH Covid-19 Treatment Guidelines. Table 4f. Characteristics of Immunomodulators. https://tinyurl.com/3jbeucyh   Accessed 3rd March 2022

 

 

For further information, please contact:

Vela Technologies plc Brent Fitzpatrick, Non-Executive Chairman James Normand, Executive Director	Tel: +44 (0) 7421 728875
Allenby Capital Limited    (Nominated Adviser and Joint Broker)	Tel: +44 (0) 20 3328 5656
Nick Athanas/Piers Shimwell
Peterhouse Capital Limited    (Joint Broker)	Tel: +44 (0) 20 7469 0930
Lucy Williams / Duncan Vasey / Eran Zucker

 

About Vela Technologies 

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDMZGGFGVFGZZZ

Close

×

RNS Number : 1267D

FD Technologies PLC

01 March 2022

 

 

1 March 2022

FD Technologies plc

("FD Technologies" or the "Group")

 

KX Strategic Partnership Agreement with Microsoft

FD Technologies (AIM: FDP.L, Euronext Growth: FDP.I) announces that it has entered into a strategic partnership agreement with Microsoft to expand the reach of its KX Insights streaming data analytics platform as more organisations look to modernise their data infrastructure for real-time decision making. Firstly, KX Insights will be embedded natively on the Microsoft Azure platform as a first class service, with KX generating revenue based on consumption. Secondly, KX has agreed to work with Microsoft to target new applications and services that will accelerate innovation and growth for organisations in the financial services sector.

KX Insights on Azure

KX recognises there is a growing demand across industries for analytics solutions that can efficiently support client needs across both real-time streaming and historic data to enable real time business-critical decisions. KX Insights on Azure will enable customers to store and access their data using complex event processing, high-performance analytics and machine learning interfaces on one unified and easy-to-use platform. Tightly integrated within Microsoft's intelligent cloud ecosystem, the platform will work seamlessly with Microsoft services.

Designed for ease of deployment and commercial adoption, KX Insights on Azure represents a first-of-its kind native integration of a third-party streaming analytics solution on Azure. It will provide a quick and easy experience for customers to boost productivity, enabling significant cost reductions over legacy systems and will contribute towards an organisation's Azure consumption commitment. This aligns incentives for Azure and KX sales teams, enabling greater collaboration and engagement on sales and marketing initiatives with enterprise clients.

Joint development for capital markets

Additionally, KX intends to work with Microsoft to develop applications and services, leveraging KX's capabilities as the world's fastest time-series database as a core building block. This collaboration aims to help the capital markets ecosystem including exchanges, buy-side firms and sell-side institutions create high-value insights that facilitate real-time decision making.

Seamus Keating, CEO of FD Technologies, said: "This strategic partnership with Microsoft accelerates our mission to enable organisations to drive value from their real-time data assets. Enterprises will benefit from the unrivalled performance, scalability and security of KX Insights optimised for Microsoft Azure. In addition, we are excited to partner with Microsoft in developing technology solutions that address the demanding requirements of financial services organisations, particularly in capital markets where KX has a market-leading position. This is a landmark agreement for KX, with significant strategic benefits supporting our growth ambitions."

Bill Borden, Corporate Vice President of Worldwide Financial Services at Microsoft said: "KX Insights delivers industry leading, real-time streaming analytics solutions that transform how firms derive insights from market data.  Combining the full range of Microsoft's Intelligent Cloud capabilities with KX technology and expertise, we look forward to empowering our capital markets and financial services customers with new, compelling solutions for faster decision-making and innovation."

 

Enquiries

For further information please contact:

 

FD Technologies plc Seamus Keating, Chief Executive Officer Ryan Preston, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44 (0) 28 3025 2242 www.fdtechnologies.com
Investec Bank plc (Nominated Adviser and Broker) Andrew Pinder Carlton Nelson Virginia Bull	+44 (0) 20 7597 5970
Goodbody (Euronext Growth Adviser and Broker) David Kearney Don Harrington Finbarr Griffin	+353 1 667 0420
J.P. Morgan Cazenove (Broker) James A. Kelly Mose Adigun	+44 (0) 20 7742 4000
FTI Consulting (PR Adviser)	+44 (0) 20 3727 1000
Matt Dixon
Dwight Burden
Elena Kalinskaya

 

About FD Technologies

FD Technologies is a group of data-driven businesses that unlock the value of insight, hindsight and foresight to drive organisations forward. The Group comprises KX, the leading technology for real-time continuous intelligence; First Derivative, which provides technology-led services in capital markets; and MRP, the only enterprise-class, predictive Accounts Based Marketing solution. FD Technologies operates from 15 offices across Europe, North America and Asia Pacific, and employs more than 3,000 people worldwide.

For further information, please visit www.fdtechnologies.com and www.kx.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGREADDFEEEAEEA

Close

×

RNS Number : 9430C

Mears Group PLC

28 February 2022

 

 28 February 2022

Mears Group PLC

(the "Group" or the "Company")

 

Contract award – Residential Living Accommodation Project

 

 

Mears (LSE: MER), the leading provider of services to the UK Housing sector, is delighted to announce that it has been awarded the new Residential Living Accommodation Project ("RLAP") contract, providing a wide range of housing services to the Defence Infrastructure Organisation ("DIO"). The award is subject to contract and the successful completion of a standstill period.

 

The new contract is for a period of up to seven years and has an annual value in excess of £50 million. Under the contract, Mears will provide a wide range of accommodation and property services to service personnel and their families across the UK. Services include property search, selection and leasing, relocation services, tenancy management, responsive repairs and maintenance. The new contract is expected to commence in April 2022.

 

Mears has been successfully providing similar services since 2016 under the predecessor Substitute Service Accommodation contract, delivering a high level of service and operational delivery, which has contributed to this successful rebid.

 

 

David Miles, Chief Executive Officer of the Group, commented:

"We are proud of the role we play within the UK's Defence Infrastructure Organisation. With this contract award we can continue to provide the highest levels of service to these key personnel and their families and value for money to the DIO. Our operating and quality KPIs on this project have been excellent and this has clearly contributed to our successful rebid. Together with our contracts with the Home Office and the Ministry of Justice, today's successful award underlines that Mears is recognised as a trusted partner for specialist housing management services across Central Government departments. This award puts the Group in an excellent position for 2022 and beyond."

 

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014), as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

 

For further information, contact:

 

Mears Group PLC

David Miles, Chief Executive Officer
Andrew Smith, Finance Director
Alan Long, Executive Director
Joe Thompson, Investor Relations	Tel: +44(0)7980 844 580
Novella Communications
Tim Robertson	Tel: +44 (0) 203 151 7008
Claire de Groot
www.mearsgroup.co.uk

 

About Mears

Mears currently employs around 5,500 people and provides services in every region of the UK. In partnership with our Housing clients, we maintain, repair and upgrade the homes of hundreds of thousands of people in communities from remote rural villages to large inner-city estates. Mears has extended its activities to provide broader housing solutions to solve the challenge posed by the lack of affordable housing and to provide accommodation and support for the most vulnerable.

We focus on long-term outcomes for people rather than short-term solutions and invest in innovations that have a positive impact on people's quality of life and on their communities' social, economic and environmental wellbeing. Our innovative approaches and market leading positions are intended to create value for our customers and the people they serve while also driving sustainable financial returns for our providers of capital, especially our shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTBCGDDIUDDGDR

Close

×

Neville Registrars is delighted to welcome Cizzle Biotechnology Holdings PLC as the newest addition to its list of client companies.

Cizzle Biotechnology is a cancer diagnostics spin-out from the University of York.

Further information can be found on the Company's website: https://cizzlebiotechnology.com/

Close

×

RNS Number : 2039C

Immotion Group PLC

21 February 2022

 

Immotion Group plc

("Immotion", the "Company" or the "Group")

 Shark Reef Aquarium Expansion and Contract Extension, and Trading Update

 

Shark Reef Aquarium Expansion and Contract Extension

Immotion, the UK-based immersive entertainment group, is pleased to announce an expansion of capacity and a contract extension at Shark Reef Aquarium, inside Mandalay Bay Resort & Casino, Las Vegas, currently the Group's largest installation.

This will see the theatre capacity increase to 48 seats from its current 36 seats, allowing greater customer throughput, especially at peak times. The current contract, which will also include the expanded capacity, will also be extended by a further 12 month period through to 31 January 2024. We envisage that the expanded theatre will be fully operational in March 2022, in time for USA Spring Break.

Capacity Expansion at Other Partner Sites

In addition to the expansion at Shark Reef Aquarium, capacity at another two of our strongest performing sites has been significantly expanded.  Our installation at Sea Life London has been increased from 8 to 14 seats and we have also doubled the capacity of our installation at Odysea Aquarium (Scottsdale, Arizona) from 6 to 12 seats. 

These expansions demonstrate the potential to make our installations a material generator of revenue for both the Group and its partners and to establish our installations as core integrated attractions in partners' venues.

 

Trading Update

Summary

Further to the trading update on 16 December 2021, the Company is pleased to confirm that unaudited H2 revenue was circa £6.6m, a 135% increase compared to unaudited revenue of £2.8m in H1 (H2 2020: £2.0m).

H2 operating cash inflow was strong, with year-end cash on hand of £1.1m, almost double the £0.6m at the half year.

Location Based Entertainment ("LBE") 

Trading in our core LBE division in the second half of 2021 has been very encouraging with unaudited revenue of £4.0m, a 74% increase compared to £2.3m in H1, and a 207% increase compared to £1.3m H2 2020.

We opened two new sites in H2 and now have a total of 49 sites (373 headsets), with 57 per cent. of headsets now located in the USA. We continue to see new interest in our 'Undersea Explorer' theatre style offering for aquariums and are now in advanced discussions with a number of major zoos regarding the first installations of our new 'Gorilla Trek' VR Theatre and we expect our first signings in the coming weeks. 

Home Based Entertainment ("HBE")

We sold circa 35,000 units of our Let's Explore Oceans product in 2021, generating unaudited revenue of £2.5m, a three-fold increase compared to £0.7m in 2020.

Whilst the sales growth was very encouraging, with the product selling out in the UK, both direct and via Amazon, and on Amazon in the USA, we were hit in the final six weeks of 2021 by very challenging logistics, which had a significant adverse impact on landed product costs. We also suffered with some stock not reaching its destination in time resulting in lost sales. The delayed stock, 5,000 units in total, will be sold throughout 2022.

The soft 'beta' launch of our Vodiac offering began late-December with invitations sent to the Let's Explore Oceans users.  We have seen over 4,350 downloads of the iOS and Android apps and over 1,250 premium VR video purchases so far. These data points have been used to further hone the headset offering which will go on sale this coming week. The product will be available online via Vodiac.com and Amazon, and through a number of new retail partners.  The blend of direct to consumer, Amazon and retail should allow us to gather sufficient data as to how to best scale this business.

Uvisan

Uvisan's total unaudited revenue for H2 was £0.4m (up from £0.1m in H1), demonstrating the value of our growing distributor and reseller network.  We now have 12 resellers and 3 distributors, located in the UK, Europe and the USA.  We are seeing growing demand for our UV sanitising cabinets.

As well as demand for our UV cabinets for sanitising a wide range of "touched" products, we see real opportunity in the enterprise, education and training XR headset and device market (virtual reality, augmented reality and mixed reality) which is set for huge growth in coming years.  Accordingly, we will focus on building a network of partners with deep roots into that sector.

Despite a number of early enquiries, we chose to delay the launch of Cleanroom in order to refine its proprietary safety and control features and we continue to believe that it has significant potential in healthcare, office and other sectors, in both new build and refurbishment projects. We are now ready to work with our growing partner network to commercialise this product.

Uvisan now has an order book of circa £0.3m and we are looking forward to a year which should see substantial growth versus 2021.

Martin Higginson, CEO, Immotion Group plc said:

"To see our core LBE business bounce back so quickly clearly demonstrates its robustness and growth potential.   We are absolutely delighted to be expanding capacity at a number of key sites, especially our largest installation at Shark Reef Aquarium, Mandalay Bay Resort & Casino which will now run through to at least January 2024.

"The launch of our new 'Gorilla Trek' VR theatre experience has been extremely well received and we look forward to signing up our first zoo partner in the coming weeks. This sector offers huge global roll out potential with many USA zoos boasting footfall well in excess of a million visitors per annum.

"Despite the logistical challenges, we sold circa 35,000 units of our Let's Explore Oceans product, as well as gaining a new distribution partner in Australia. Vodiac will carry forward the key learning so far in order to provide a broader product offering to a wider audience. We believe there is a real opportunity to democratise the home VR video market. Our offering of a VR headset, combined with original and curated VR content at a sub £30 price tag will, we believe, allow us to build an audience of scale.

"Our Uvisan products continued to sell well, with a growing roster of distribution partners, including in Australia and the USA.

"Overall, we feel we have made good progress across the company and are looking forward with renewed confidence."

 

Enquiries:

For further information please visit www.immotion.co.uk, or contact:

 

Immotion Group plc	Martin Higginson David Marks	[email protected]
WH Ireland Limited (Nomad and Joint Broker)	Adrian Hadden  Jessica Cave Darshan Patel Ben Good	Tel + 44 (0) 207 220 1666
Alvarium Capital Partners (Joint Broker)	Alex Davies	Tel: +44 (0) 207 195 1458

 

Shard Capital Partners LLP (Co-Broker)

Damon Heath Erik Woolgar

Tel: +44 (0) 20 7186 9900

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulaon (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TSTQBLFLLLLXBBQ

Close

×

RNS Number : 2163B

Crimson Tide PLC

10 February 2022

 

10 February 2022

Crimson Tide Plc

("Crimson Tide" or "the Company")
 

Significant Contract Win and New Partnership

Crimson Tide Plc (TIDE) is delighted to announce both a substantial new contract win and, separately, an expansive strategic partnership with Cisco Meraki. The new client is a market leading contract catering company, who will be using mpro5 to digitise all their daily logbooks to ensure the highest standards of food safety are met for their clients.

Data visualisation via custom built Microsoft Power BI dashboards, will provide invaluable real-time insights for the client and empower the business to make more informed decisions in their operations.

The fully digitised solution will be rolled out across the client's several hundred UK sites. The total subscription contract value exceeds £400,000 across its initial term.

The new strategic partnership presents great opportunities for both the Company and Cisco Meraki. Crimson Tide's platform, mpro5, turns Cisco Meraki Internet of Things (IoT) products into solutions for its customers, leveraging data gathered from sensors and smart cameras for automation, action, visibility and business insight.

This combined solution is highly versatile and can be deployed in a variety of contexts – mpro5 has been productised for the Cisco Meraki marketplace, featuring Smart Schools, Stations, Data Centres, Coffee Shops & Quick Service Restaurants and Buildings. The marketplace listing is available to all Cisco Meraki partners, providing scope for further opportunities and partnerships.

Both parties expect this partnership to allow them to deliver comprehensive and effective solutions for their current customer base and reseller network, as well as new prospects globally.

Barrie Whipp, Chairman, commented: "Our contract win continues to demonstrate the value of mpro5 in catering, an area where we now have a great understanding of the standards required in health and safety. The key to our offering is the level of service we offer to our clients on an ongoing basis. I am particularly pleased with the new partnership with Cisco Meraki. Their global reach and the availability of the Cisco Meraki marketplace means that mpro5 is now able to reach markets outside our traditional geographies. We look forward to implementing mpro5 with Cisco Meraki sensors in a wide range of vertical markets"

 

For further information:

Crimson Tide plc Barrie Whipp / Luke Jeffrey 01892 542 444

finnCap (Nominated Adviser and Broker)

Corporate Finance: Julian Blunt / James Thompson +44 20 7220 0500

Corporate Broking: Andrew Burdis +44 20 7220 0500

Alma PR (Financial PR)

Josh Royston +44 7780 901979

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTFLFFDFEIAIIF

Close

×

RNS Number : 4554A

Solid State PLC

03 February 2022

 

 

Reach – non regulatory announcement

 

 

Solid State plc

( "Solid State", the " Group " or the "Company" )

£ Multi-million contract with BAE Systems

 

Solid State plc (AIM: SOLI), the specialist value added component supplier and design-in manufacturer of computing, power, and communications products, announces that following a pre-qualification stage and a competitive tender process, BAE Systems has awarded Steatite Ltd, the manufacturing arm of Solid State Plc, a multi-million pound contract to design, develop and qualify computer consoles for maritime platforms. The multi-function use of the console will need to comply with many industry and MOD specific standards. This challenging set of requirements required an approach that offered innovation, value and agility. 

 

A BAE Systems' representative, said: "This is a critical path programme and our expectations are high.  Steatite provided us with the assurance that they have the technical skills, resources and commitment to deliver against challenging timescales and meeting commercial constraints.  We are looking forward to working with the team on the project." 

 

Matthew Richards, Managing Director at Steatite, added: "We have worked with BAE Systems for many years on maritime and land based systems. I am delighted that our recent investments in test and security infrastructure and personnel combined with our existing engineering expertise has been recognised by BAE Systems.  We have hit the ground running on the project and look forward to a long and mutually beneficial relationship with BAE Systems."

 

The project will be led from the Redditch site utilising the new EMC facility installed in 2021 whilst drawing on technical skills from the Solid State Group.

 

For further information please contact:

 

Solid State plc Gary Marsh – Chief Executive Peter James – Group Finance Director	Via Walbrook
Walbrook PR (Financial PR)  Tom Cooper / Nick Rome	020 7933 8780 0797 122 1972 [email protected]

 

 

Analyst Research Reports: For further analyst information and research see the Solid State plc website: https://solidstateplc.com/research/

 

 

Notes to Editors:

 

Solid State plc (SOLI) is a value added electronics group supplying commercial, industrial and military markets with durable components, assemblies and manufactured units for use in specialist and harsh environments.  The Group's mantra is – 'Trusted technology for demanding applications'.  To see an introductory video on the Group –  https://bit.ly/3kzddx7  

 

Operating through two main divisions: Systems (Steatite & Active Silicon) and Components (Solid State Supplies, Pacer, Willow Technologies & AEC); the Group specialises in complex engineering challenges often requiring design-in support and component sourcing for computing, power, communications, electronic, electro-mechanical and opto-electronic products.

 

Headquartered in Redditch, UK, Solid State employs approximately 300 staff across UK and US, serving specialist markets in industrial, defence and security, transportation, medical and energy. 

 

Solid State was established in 1971 and admitted to AIM in June 1996.  The Group has grown organically and by acquisition – having made 12 acquisitions since 2002.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGIGDDLXGDGDD

Close

×

RNS Number : 5117A

NetScientific PLC

02 February 2022

 

NetScientific plc

("NetScientific", the "Group" or the "Company")

 

PDS Phase 2 Trial Update

 

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

 

London, UK – 2 February 2022  – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced that its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective response benchmarks.

The trial, which studies PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), will now progress to full enrolment of 54 patients in this group of checkpoint inhibitor (CPI) naïve patients. As pre-specified in the clinical trial design, the achievement of an objective response as measured by radiographic tumour responses according to RECIST 1.1 (tumour reduction of 30% or more) confirmed by two separate measurements among at least four or more of the first 17 patients in the CPI naïve arm allows that arm to progress to full enrolment. We anticipate these data will be presented in more detail at an upcoming medical conference. 

VERSATILE-002, being conducted in collaboration with Merck (known as MSD outside the US and Canada), is being studied in two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread. The first group have not been previously treated with a checkpoint inhibitor (CPI naïve). An initial assessment of the combination in a second group of 21 patients who have failed prior therapy with checkpoint inhibitors (CPI refractory) is ongoing.  

Dr. Jared Weiss, Section Chief of Thoracic and Head and Neck Oncology at the University of Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Centre, is serving as the Lead Principal Investigator of VERSATILE-002.

Dr. Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech said: " The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform's potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression.

"The initial data solidifies our belief that PDS0101's demonstrated preclinical efficacy when combined with KEYTRUDA® has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers."

Dr. Ilian Iliev, CEO of NetScientific, commented: "The move to full patient recruitment in this Phase 2 trial is a very meaningful step in PDS' Phase 2 trial. We look forward to the company's continued progress on its multiple clinical programmes."

The full text of the announcement from PDS Biotechnology is reproduced below and is available online here: https://pdsbiotech.com/investors/news-center/press-releases/press-releases1/118-2022-news/590-iotechnnouncesreliminaryfficacychievementin20220202

###

FLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective response benchmarks. The trial, which studies PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), will now progress to full enrollment of 54 patients in this group of checkpoint inhibitor (CPI) naïve patients. As pre-specified in the clinical trial design, the achievement of an objective response as measured by radiographic tumor responses according to RECIST 1.1 (tumor reduction of 30% or more) confirmed by two separate measurements among at least four or more of the first 17 patients in the CPI naïve arm allows that arm to progress to full enrollment. We anticipate these data will be presented in more detail at an upcoming medical conference. 

VERSATILE-002, being conducted in collaboration with Merck (known as MSD outside the US and Canada), is being studied in two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread. The first group have not been previously treated with a checkpoint inhibitor (CPI naïve). An initial assessment of the combination in a second group of 21 patients who have failed prior therapy with checkpoint inhibitors (CPI refractory) is ongoing.  

"The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform's potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression," commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. "The initial data solidifies our belief that PDS0101's demonstrated preclinical efficacy when combined with KEYTRUDA® has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers."

Dr. Jared Weiss, Section Chief of Thoracic and Head and Neck Oncology at the University of Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center, is serving as the Lead Principal Investigator of VERSATILE-002. Patients interested in enrolling in this clinical study should email [email protected] or visit the website at http://pdsbiotech.com/VERSATILE-002 to learn more.

 

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technology platforms.

Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.  The Company's pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.  

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

 

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast," "guidance", "outlook" and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company's ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company's product candidates, if approved; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company's product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

###

 

 

For more information, please contact:

 

NetScientific	Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel	+44 (0)20 7220 1666
Walbrook PR	+44 (0)20 7933 8780 or [email protected]
Nick Rome / Nicholas Johnson / Paul McManus	07748 325 236 / 07884 664 686 / 07980 541 893

 

 

 

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities. 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website: netscientific.net ).

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUUVSRUSUURAR

Close

×

RNS Number : 9106Z

ACP Energy PLC

28 January 2022

 

 

 

 

28 January 2022

ACP ENERGY PLC

("ACP" or "the Company")

Admission to Trading on London Stock Exchange & First Day of Dealings

ACP Energy Plc is a newly formed company set to capture value accretive opportunities in the oil & gas industry.  The Company is pleased to announce that admission to trading on the London Stock Exchange's Main Market, Standard Segment, via a Special Purpose Acquisition Company ("SPAC"), will take place and dealings will commence at 8.00 a.m. today under the ticker ACPE.L.

Paul Welch, ACP Energy Plc's Chairman, commented:

"We are very pleased to have successfully listed ACP on the London Stock Exchange, via a Special Purpose Acquisition Company.  ACP is focused on acquiring hydrocarbon producing assets that are either in production or near to production, bringing swift cash flow generation and ensuring early business stability.  Whilst listing is an important milestone, we now begin the work of bringing our collective experience to bear in identifying significant acquisition opportunities upon which we can grow the business.  At a time of transition in the energy markets, there remains a significant global demand for new sources of oil and gas.  Throughout this period, the Board is committed to the highest standards of Environmental, Social and Governance practices and looks forward to providing further updates to the market in due course."

 

Strategy

 

The Company will focus on acquiring opportunities within the upstream segment of the oil and gas industry, in areas such as appraisal, development and production, focusing particularly on projects with identified oil and/or natural gas reserves and resources. 

 

The Company has identified the following criteria for the purpose of reviewing and evaluating opportunities:

· Sectoral Focus: ACP intends to focus on opportunities in the upstream oil and natural gas sector. The Company will have a particular focus on producing assets, that require additional investment to increase the production and reserves base. The Company believes that there are significant opportunities in the upstream oil and gas sector and, in particular, existing producing assets that will generate value for Shareholders.  ACP, together with its advisers, has extensive global networks within the sector from which to solicit and assess opportunities.

 

· Development Profile: The Company intends to focus on producing assets that have not received sufficient investment capital due to either local fiscal issues or previous downturns in commodity prices. Such assets will likely have had some development work undertaken to establish a minimum base of production or resource which, for whatever reason, now requires further funding, in order to either fully develop the opportunity or to either return it to or increase its production.  ACP therefore expects to focus on opportunities where the asset will be revenue generating, either immediately upon acquisition or within a reasonable timeframe following completion of the work program.  The Company believes that this strategy will balance investment risk against generating long-term shareholder value.

· Geography:   The Company does not propose to limit its search to any specific geographic location; however, the geographic location of any investment opportunity will be suitable for institutional investment within the London market.  The assets may be located anywhere in the world, but the Company will primarily be looking at opportunities in proven hydrocarbon producing jurisdictions with established oil and gas infrastructure. 

 

· Opportunity Identification : The Company, through its broad range of contacts plans to identify, originate, structure and finance oil and gas transactions that generate value for its shareholders.  The Company will use its internal research to identify and assess potential opportunities and will then initiate discussions directly or via market contacts and professional advisers.

 

· Operator: Following the completion of an Acquisition, the objective of the Company is to be involved in the operations of the acquired business.  The Company envisions that additional opportunities will be available to it by taking an active role in the management through appraisal activity, operational improvements, capacity expansions and funding working capital.  Operational management is anticipated to provide superior insight into a particular sector or operating region allowing value accretive complementary acquisitions to be made.

 

· Value Creation: The Company's long-term aim is to create shareholder value by investing in projects with dependable cashflows and build a portfolio where there is large potential upside in value by providing vital finance and expertise enabling an asset or business to achieve its full potential. ACP is committed to the highest standards of governance and to fulfilling its corporate responsibilities by making meaningful economic and social contributions in the areas where it operates.

 

 

For further information:

www.acpenergyplc.com

 

ACP Energy

Paul Welch, Executive Chairman     +44 207 193 2376 / [email protected]

 

Celicourt Communications

Mark Antelme / Jimmy Lea                                                            +44 208 434 2643 / [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

LISPPUQWGUPPGRM

Close